GR3027 reversal of neurosteroid-induced, GABA-A receptor-mediated inhibition of human brain function: an allopregnanolone challenge study

• Published in: Psychopharmacology Vol. 235; no. 5; pp. 1533 - 1543
• Main Authors: Johansson, Maja, Månsson, Maria, Lins, Lars-Eric, Scharschmidt, Bruce, Doverskog, Magnus, Bäckström, Torbjörn
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01-05-2018; Springer; Springer Nature B.V
• Subjects: Adult; Allopregnanolone; Allosteric properties; Analysis; Anesthesia; Anesthetics - pharmacology; Biomedical and Life Sciences; Biomedicine; Brain; Brain - drug effects; Brain - physiology; Clinical trial; Clinical trials; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug dosages; GABA; GABA-A Receptor Antagonists - pharmacology; GR3027; Humans; Inhibition; Male; Males; Medical research; Medicin och hälsovetenskap; Neurosciences; Neurosteroids; Neurotransmitter Agents - antagonists & inhibitors; Neurotransmitter Agents - pharmacology; Neurotransmitters; Original Investigation; Pharmacokinetics; Pharmacology/Toxicology; Pregnanolone; Pregnanolone - antagonists & inhibitors; Pregnanolone - pharmacology; Psychiatry; Psychopharmacology; Receptors, GABA-A - physiology; Saccades - drug effects; Saccades - physiology; Saccadic eye movement; Saccadic eye movements; Sedation; Sleep; Toxicity; Wakefulness - drug effects; Wakefulness - physiology; Young Adult; γ-Aminobutyric acid A receptors; Canada; Sweden; Clinical trial; Sedation; GR3027; Allopregnanolone; Saccadic eye movement
• ISSN: 0033-3158; 1432-2072; 1432-2072
• DOI: 10.1007/s00213-018-4864-1

Rationale
GR3027 is a novel small molecule GABA-A receptor-modulating steroid antagonist, which in non-clinical studies has shown promise for treatment of human disorders due to allosteric over-activation of GABA-A receptors by neurosteroids, such as allopregnanolone. We here studied its safety, pharmacokinetics, and ability to inhibit allopregnanolone effects in humans.
Methods
Safety and pharmacokinetics were studied in healthy adult males receiving ascending single or multiple oral GR3027 vs. placebo. GR3027-mediated reversal of allopregnanolone effect on maximal saccadic eye velocity (SEV), and self-rated somnolence was studied in a double-blind, placebo-controlled, three-part cross-over study in which 3 or 30 mg oral GR3027 preceded 0.05 mg/kg of i.v. allopregnanolone.
Results
GR3027 was well tolerated, adverse events were generally mild and transient, and no dose-limiting toxicity or grade 3 adverse events were observed up to the highest single (200 mg) or multiple (100 mg every 12 h for 5 days) doses. The maximum concentration (
C
max
) and systemic exposure (area under the plasma concentration-time curve from dose extrapolated to infinity [AUC
0–∞
] and/or AUC during the dosing interval [AUC
τ
]) varied linearly with dose; with dose-dependent accumulation ratios of 1.3–1.6. Allopregnanolone decreased SEV and induced somnolence in most, but not all subjects. By predefined analyses, 30 mg GR3027 significantly inhibited allopregnanolone-induced decrease in SEV (
p
 = 0.03); 3 and 30 mg GR3027 non-significantly inhibited allopregnanolone-induced sedation. By post hoc analyses restricted to subjects with allopregnanolone-induced changes and the time period over which they occurred, GR3027 dose dependently inhibited allopregnanolone-induced decrease in SEV (
p
 = 0.04 at 30 mg, non-significant at 3 mg) and allopregnanolone-induced sedation (
p
 = 0.01/0.05 at 3/30 mg doses).
Conclusion
Oral GR3027 mitigates inhibition of brain function induced by allopregnanolone at doses which are clinically well tolerated and associated with linear pharmacokinetics.